BRAF and neoplasm: Tumor molecular profiling was retrieved from clinical documentation when available: 62% (n = 44/71) were KRAS mutant, 3% (n = 2/58) NRAS mutant, 4% (n = 3/68) BRAF mutant and 20% (n = 6/30) HER2 amplified.